Life Sciences Products & Reviews

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

The Twist 96-Plex Library Preparation kit enables high-throughput library construction for whole genome sequencing. 

The Twist Alliance CeGaT RNA Fusion Panel is a targeted RNA sequencing solution designed to detect both known and novel gene fusions across 160 genes associated with over 30 cancer types, enhancing cancer and precision medicine research.

Twist Exome 2.0 is a comprehensive exome sequencing panel designed to detect rare and inherited diseases, as well as germline cancers. Its high uniformity and low off-target rate deliver best-in-class sequencing efficiency, enabling quality data collection with less sequencing.

For best-in-class results, use best-in-class tools

Delivers excellent uniformity and increased on-target rates

The Twist Standard Hybridization Reagent Kit v2 is the gold standard for efficient and specific binding of panel probes to your regions of interest. Coupled with Twist’s Catalog or Custom Panels, this standard hybridization workflow provides the optimal conditions for a broad range of content.

Enables sequencing of genes that are difficult or impossible to fully sequence with short read technology. 

Focus on important genes in pharmacogenomics that are critical to drug metabolism and patient therapeutic response.

Twist Diversity SNP Panel gives researchers a new flexible ethnicity-neutral gold standard to use for GBS

Deep coverage of clinically focused targets that allow for the study of methylation patterns that may be relevant to early cancer detection and diagnosis from tumor and liquid biopsy samples.

Streamline the identification of heritable disease-linked alleles, be it through carrier screening or pre- and post-natal testing.

The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples.

The Twist Alliance Canine Exome developed in collaboration with the Broad Institute

The Twist Alliance CNTG Exome - 41 MB provides highly uniform coverage of the entire exome as well as full coverage of the mitochondrial genome.